In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer.


Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
12 2020
Historique:
received: 08 05 2020
revised: 22 09 2020
accepted: 25 09 2020
entrez: 9 10 2020
pubmed: 10 10 2020
medline: 14 7 2021
Statut: epublish

Résumé

Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit because of emerging resistance. To identify candidate therapeutic gene targets, we applied a murine prostate cancer orthograft model that recapitulates clinical invasive prostate cancer in a genome-wide CRISPR/Cas9 screen under docetaxel treatment pressure. We identified 17 candidate genes whose suppression may enhance the efficacy of docetaxel, with transcription elongation factor A-like 1 (

Identifiants

pubmed: 33033111
pii: 3/12/e202000770
doi: 10.26508/lsa.202000770
pmc: PMC7556750
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
TCEAL1 protein, human 0
Taxoids 0
Transcription Factors 0
Docetaxel 15H5577CQD

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2020 Rushworth et al.

Références

Clin Med Insights Oncol. 2016 Oct 09;10(Suppl 1):57-66
pubmed: 27773999
Cancer Res. 2017 Jun 15;77(12):3158-3168
pubmed: 28515147
PLoS One. 2013 Dec 04;8(12):e79456
pubmed: 24324581
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Bioessays. 2000 Apr;22(4):327-36
pubmed: 10723030
Genome Biol. 2014;15(12):554
pubmed: 25476604
EMBO Mol Med. 2018 Apr;10(4):
pubmed: 29540470
Caries Res. 2019;53(2):228-233
pubmed: 30149392
Oncogene. 2014 Nov 27;33(48):5511-5522
pubmed: 24276237
Trends Cancer. 2018 May;4(5):349-358
pubmed: 29709259
Nat Methods. 2015 Feb;12(2):115-21
pubmed: 25633503
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Mol Cell. 2014 Jun 5;54(5):805-19
pubmed: 24793696
Mol Cell. 2001 May;7(5):959-70
pubmed: 11389843
J Bacteriol. 2018 Mar 12;200(7):
pubmed: 29358495
Nat Commun. 2018 Oct 15;9(1):4275
pubmed: 30323222
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Genome Biol. 2014;15(12):550
pubmed: 25516281
Oncogene. 2008 Dec 11;27(58):7223-34
pubmed: 18806825
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11002-6
pubmed: 7971997
Br J Cancer. 2020 Feb;122(4):517-527
pubmed: 31844184
Nature. 2017 Jul 27;547(7664):413-418
pubmed: 28723893
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Mol Cancer Ther. 2008 Sep;7(9):3006-17
pubmed: 18790781
BMC Cancer. 2010 Oct 22;10:576
pubmed: 20969748
BMC Cancer. 2006 Nov 01;6:260
pubmed: 17076909
Nucleic Acids Res. 2018 Jan 4;46(D1):D754-D761
pubmed: 29155950
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
F1000Res. 2018 Aug 24;7:1338
pubmed: 30254741
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Gene. 1994 Jun 10;143(2):285-7
pubmed: 8206389
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Dis Esophagus. 2005;18(1):37-40
pubmed: 15773840
J Clin Invest. 2013 Mar;123(3):1157-75
pubmed: 23434594
Cancer Cell Int. 2019 Jan 8;19:12
pubmed: 30636933
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Cell. 2015 Mar 12;160(6):1246-60
pubmed: 25748654
Genomics. 1999 Mar 1;56(2):217-20
pubmed: 10051408
Am J Hum Genet. 2009 Nov;85(5):699-705
pubmed: 19853237

Auteurs

Linda K Rushworth (LK)

Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Cancer Research UK Beatson Institute, Glasgow, UK.

Victoria Harle (V)

Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Cancer Research UK Beatson Institute, Glasgow, UK.

Peter Repiscak (P)

Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Cancer Research UK Beatson Institute, Glasgow, UK.

William Clark (W)

Cancer Research UK Beatson Institute, Glasgow, UK.

Robin Shaw (R)

Cancer Research UK Beatson Institute, Glasgow, UK.

Holly Hall (H)

Cancer Research UK Beatson Institute, Glasgow, UK.

Martin Bushell (M)

Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Cancer Research UK Beatson Institute, Glasgow, UK.

Hing Y Leung (HY)

Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK h.leung@beatson.gla.ac.uk.
Cancer Research UK Beatson Institute, Glasgow, UK.

Rachana Patel (R)

Cancer Research UK Beatson Institute, Glasgow, UK.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH